HQ Team
October 10, 2026: GSK Plc will invest $800 million in Montgomery, Pennsylvania to build a biopharmaceutical innovation and manufacturing hub, according to the state governor Josh Shapiro.
The new facility will integrate commercial production, research and development, and advanced digital capabilities at a single site and GSK’s expansion was slated to create more than 300 new jobs over the next five years, retain approximately 4,500 existing full-time jobs across the Commonwealth of Pennsylvania, according to a statement from the governor’s office.
It will continue “growing Pennsylvania’s robust life sciences industry. GSK is expanding its facilities in Upper Merion Township, with construction planned to begin in 2027.”
The facility marks GSK’s second major expansion in Pennsylvania since the governor took office, previously investing $800 million in Lancaster County — investing a total of nearly $1.7 billion in the Commonwealth, according to the statement.
Doubling capacity
In October 2024, the state administration announced GSK’s $800 million facility expansion in Marietta, Lancaster County, doubling the site’s size and capacity. The project was the largest Commonwealth supported economic development project in Lancaster County’s history. GSK Plc’s US headquarters is in Philadelphia, with global headquarters located in London, England.
“GSK could have chosen anywhere in the world to expand production, but once again, they chose to renew and deepen their commitment to both the Commonwealth and our workers,” said governor Shapiro. “When companies like GSK double down on their commitment to Pennsylvania, we create more opportunities across the Commonwealth, spur meaningful economic growth, and support our skilled workforce.”
GSK will be eligible for tax benefits through the Qualified Manufacturing Innovation and Reinvestment Deduction (QMIRD) program and the Manufacturing Tax Credit (MTC) program. “GSK’s decision to make another major investment in Pennsylvania is a strong signal that we have the innovation ecosystem, talent, and infrastructure to support the next generation of biopharmaceutical manufacturing,” said Rick Siger, Secretary of the Department of Community and Economic Development.
The expansion project will include the demolition of existing buildings and construction of new and enhanced facilities including a commercial-scale biologics manufacturing facility “capable of supporting both clinical and commercial supply,” a co-located research and development pilot plant to accelerate tech transfer and process development, and a centralized quality control lab and manufacturing science & technology (MSAT) hub.
J&J, Eli Lilly
Life sciences companies like Johnson & Johnson, Eli Lilly, Eurofins Lancaster Laboratories, and B. Braun have announced major expansions in Pennsylvania. The state’s life sciences industry is home to about 3,900 companies, employs more than 110,000 Pennsylvanians, and directly contributes $73 billion to the economy, according to the statement.
Data from the US Bureau of Labor Statistics shows that Pennsylvania ranks among the top states in the nation for five-year new business survival, according to the statement.
